Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Express Scripts
AstraZeneca
Moodys
Johnson and Johnson

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR VECURONIUM BROMIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Vecuronium Bromide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00970762 ↗ Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 2003-02-01 This study was conducted to determine and compare the safety and effectiveness of two neuromuscular blockers (rocuronium and vecuronium) at various doses in adults who are undergoing general elective surgery with sevoflurane anesthesia. Study participants received an intubating dose of a neuromuscular blocker (to enable insertion of a tube through the nose or mouth into the trachea to provide artificial ventilation). The intubating dose was followed by repeated bolus maintenance doses as needed, to maintain muscle relaxation. The time it takes to reach maximal effect of the neuromuscular blocker (onset time) after the intubating dose was measured and compared as the primary outcome.
NCT01116713 ↗ Effect of Dexamethasone in Postoperative Symptoms After Mastectomy for Breast Cancer Completed Instituto Mexicano del Seguro Social Phase 3 2009-06-01 Postoperative pain, nausea and vomiting (PONV) are the most common complications after anesthesia and surgery. Women undergoing mastectomy with axillary dissection are at a particularly high risk for the development of PONV and an incidence of 60-80% in patients receiving no antiemetic has been reported. Emetic episodes predispose to aspiration of gastric contents, wound dehiscence, psychological distress, and delayed recovery and discharge times. These justify the use of prophylactic antiemetics in women scheduled for mastectomy. Most of the currently used antiemetics, including antihistamines, butyrophenones and dopamine receptor antagonists have been reported to cause occasional undesirable adverse effects, such as excessive sedation, hypotension, dry mouth, dysphoria, hallucinations and extrapyramidal signs. Antiserotonins (e.g., ondansetron) are available for the prevention and treatment of PONV in patients undergoing various types of surgery [4]. However, the use of prophylactic antiemetic therapy with antiserotonins has been criticized for being too expensive. Dexamethasone was first reported to be an effective antiemetic regimen in patients receiving cancer chemotherapy. The purpose of this study was to evaluate the efficacy of dexamethasone treatment for reducing pain and PONV as well as analgesic and antiemetic requirements in women undergoing general anesthesia for mastectomy with axillary lymph node dissection.
NCT01690338 ↗ A Study of Residual Curarization Incidence in China Unknown status Central South University Phase 4 2012-10-01 The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.
NCT01690338 ↗ A Study of Residual Curarization Incidence in China Unknown status China Medical University Hospital Phase 4 2012-10-01 The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.
NCT01690338 ↗ A Study of Residual Curarization Incidence in China Unknown status Chinese PLA General Hospital Phase 4 2012-10-01 The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vecuronium Bromide

Condition Name

Condition Name for Vecuronium Bromide
Intervention Trials
Anesthesia 4
Pediatric Cancer 1
Pediatric Hepatoblastoma 1
Pediatric Tumor 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vecuronium Bromide
Intervention Trials
Thalassemia 1
Pain, Postoperative 1
Ventricular Dysfunction 1
Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vecuronium Bromide

Trials by Country

Trials by Country for Vecuronium Bromide
Location Trials
United States 30
China 12
Austria 3
India 2
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vecuronium Bromide
Location Trials
Ohio 2
California 2
Pennsylvania 2
Tennessee 2
North Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vecuronium Bromide

Clinical Trial Phase

Clinical Trial Phase for Vecuronium Bromide
Clinical Trial Phase Trials
Phase 4 7
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vecuronium Bromide
Clinical Trial Phase Trials
Completed 7
Unknown status 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vecuronium Bromide

Sponsor Name

Sponsor Name for Vecuronium Bromide
Sponsor Trials
Merck Sharp & Dohme Corp. 3
Postgraduate Institute of Medical Education and Research 2
The First Teaching Hospital of Xinjiang Medical University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vecuronium Bromide
Sponsor Trials
Other 33
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
AstraZeneca
Baxter
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.